The Centers for Medicare & Medicaid Services today announced five new Center for Medicare and Medicaid Innovation payment models aimed at transforming kidney care so that patients with chronic kidney disease have access to high-quality, coordinated care. The proposed End-Stage Renal Disease Treatment Choices model would be mandatory for certain areas of the country; four other models are voluntary. The ETC model, which would include dialysis facilities and managing clinicians, would provide new incentives to encourage dialysis in the home. The payment adjustments under the proposed ETC model would begin Jan. 1, 2020, and end June 30, 2026. CMMI said the four optional payment models are expected to enroll more than 200,000 Medicare patients in arrangements that give providers new incentives for preventing kidney disease and managing kidney patients’ health more comprehensively. The payment models are in response to an executive order signed today by President Trump on advancing kidney health. 

Related News Articles

Headline
The White House May 22 released its Make America Healthy Again report that focuses on childhood chronic disease. The report highlights findings from the MAHA…
Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate…
Headline
The Food and Drug Administration May 16 announced it cleared the first blood test to diagnose Alzheimer’s disease. The test, created by Fujirebio Diagnostics,…
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law…
Headline
The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models. “The 340B…
Headline
The AHA May 8 filed an amicus brief in the U.S. District Court for the District of Nebraska in defense of the state’s 340B contract pharmacy law prohibiting…